LPL Financial LLC Grows Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

LPL Financial LLC increased its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 418.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 128,126 shares of the company's stock after purchasing an additional 103,424 shares during the quarter. LPL Financial LLC's holdings in Dr. Reddy's Laboratories were worth $2,023,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in RDY. Robeco Institutional Asset Management B.V. increased its position in shares of Dr. Reddy's Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after buying an additional 9,373,412 shares during the period. Van ECK Associates Corp lifted its stake in Dr. Reddy's Laboratories by 609.4% in the 4th quarter. Van ECK Associates Corp now owns 5,838 shares of the company's stock worth $92,000 after purchasing an additional 5,015 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Dr. Reddy's Laboratories by 400.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock valued at $8,373,000 after purchasing an additional 427,573 shares during the period. World Investment Advisors LLC purchased a new position in shares of Dr. Reddy's Laboratories during the 3rd quarter valued at $3,459,000. Finally, Crossmark Global Holdings Inc. increased its holdings in shares of Dr. Reddy's Laboratories by 328.3% in the fourth quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company's stock worth $201,000 after purchasing an additional 9,781 shares during the period. Hedge funds and other institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Price Performance

NYSE RDY traded up $0.25 during trading on Friday, reaching $13.69. The company's stock had a trading volume of 2,412,404 shares, compared to its average volume of 1,443,151. The firm has a fifty day moving average of $13.16 and a 200 day moving average of $14.27. Dr. Reddy's Laboratories Limited has a one year low of $12.26 and a one year high of $16.89. The stock has a market capitalization of $11.42 billion, a PE ratio of 21.79 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.